{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:26:00Z","timestamp":1791390360688,"version":"4.3.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatic leukemia factor (HLF) is aberrantly expressed in human malignancies. However, the role of HLF in the regulation of ovarian cancer (OC) remains unknown. Herein, we reported that HLF expression was upregulated in OC tissues and ovarian cancer stem cells (CSCs). Functional studies have revealed that HLF regulates OC cell stemness, proliferation, and metastasis. Mechanistically, HLF transcriptionally activated Yes-associated protein 1 (YAP1) expression and subsequently modulated the Hippo signaling pathway. Moreover, we found that miR-520e directly targeted HLF 3\u2032-UTR in OC cells. miR-520e expression was negatively correlated with HLF and YAP1 expression in OC tissues. The combined immunohistochemical (IHC) panels exhibited a better prognostic value for OC patients than any of these components alone. Importantly, the HLF\/YAP1 axis determines the response of OC cells to carboplatin treatment and HLF depletion or the YAP1 inhibitor verteporfin abrogated carboplatin resistance. Analysis of patient-derived xenografts (PDXs) further suggested that HLF might predict carboplatin benefits in OC patients. In conclusion, these findings suggest a crucial role of the miR-520e\/HLF\/YAP1 axis in OC progression and chemoresistance, suggesting potential therapeutic targets for OC.<\/jats:p>","DOI":"10.1038\/s41419-023-06076-5","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T14:17:03Z","timestamp":1694701023000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["HLF promotes ovarian cancer progression and chemoresistance via regulating Hippo signaling pathway"],"prefix":"10.1038","volume":"14","author":[{"given":"Tao","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingsong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1386-8082","authenticated-orcid":false,"given":"Daimin","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6441-4040","authenticated-orcid":false,"given":"Lei","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8354-2224","authenticated-orcid":false,"given":"Hengyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubei","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"6076_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"6076_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.semcancer.2021.08.005","volume":"77","author":"MA Khan","year":"2021","unstructured":"Khan MA, Vikramdeo KS, Sudan SK, Singh S, Wilhite A, Dasgupta S, et al. Platinum-resistant ovarian cancer: from drug resistance mechanisms to liquid biopsy-based biomarkers for disease management. Semin Cancer Biol. 2021;77:99\u2013109.","journal-title":"Semin Cancer Biol"},{"key":"6076_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-1130-z","volume":"19","author":"S Munoz-Galvan","year":"2020","unstructured":"Munoz-Galvan S, Felipe-Abrio B, Verdugo-Sivianes EM, Perez M, Jimenez-Garcia MP, Suarez-Martinez E, et al. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness. Mol Cancer. 2020;19:7.","journal-title":"Mol Cancer"},{"key":"6076_CR4","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.1158\/1078-0432.CCR-17-3697","volume":"24","author":"F Simpkins","year":"2018","unstructured":"Simpkins F, Jang K, Yoon H, Hew KE, Kim M, Azzam DJ, et al. Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells. Clin Cancer Res. 2018;24:4874\u201386.","journal-title":"Clin Cancer Res"},{"key":"6076_CR5","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1101\/gad.6.9.1608","volume":"6","author":"SP Hunger","year":"1992","unstructured":"Hunger SP, Ohyashiki K, Toyama K, Cleary ML. Hlf, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia. Genes Dev. 1992;6:1608\u201320.","journal-title":"Genes Dev"},{"key":"6076_CR6","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1101\/gad.301404","volume":"18","author":"F Gachon","year":"2004","unstructured":"Gachon F, Fonjallaz P, Damiola F, Gos P, Kodama T, Zakany J, et al. The loss of circadian PAR bZip transcription factors results in epilepsy. Genes Dev. 2004;18:1397\u2013412.","journal-title":"Genes Dev"},{"key":"6076_CR7","doi-asserted-by":"publisher","first-page":"R1013","DOI":"10.1152\/ajpregu.00241.2010","volume":"299","author":"Q Wang","year":"2010","unstructured":"Wang Q, Maillard M, Schibler U, Burnier M, Gachon F. Cardiac hypertrophy, low blood pressure, and low aldosterone levels in mice devoid of the three circadian PAR bZip transcription factors DBP, HLF, and TEF. Am J Physiol Regul Integr Comp Physiol. 2010;299:R1013\u20139.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"6076_CR8","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1182\/blood-2006-10-054676","volume":"109","author":"M Magnusson","year":"2007","unstructured":"Magnusson M, Brun AC, Miyake N, Larsson J, Ehinger M, Bjornsson JM, et al. HOXA10 is a critical regulator for hematopoietic stem cells and erythroid\/megakaryocyte development. Blood. 2007;109:3687\u201396.","journal-title":"Blood."},{"key":"6076_CR9","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.celrep.2017.10.112","volume":"21","author":"M Wahlestedt","year":"2017","unstructured":"Wahlestedt M, Ladopoulos V, Hidalgo I, Sanchez Castillo M, Hannah R, Sawen P, et al. Critical modulation of hematopoietic lineage fate by hepatic leukemia factor. Cell Rep. 2017;21:2251\u201363.","journal-title":"Cell Rep"},{"key":"6076_CR10","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1084\/jem.20181399","volume":"216","author":"T Yokomizo","year":"2019","unstructured":"Yokomizo T, Watanabe N, Umemoto T, Matsuo J, Harai R, Kihara Y, et al. Hlf marks the developmental pathway for hematopoietic stem cells but not for erythro-myeloid progenitors. J Exp Med. 2019;216:1599\u2013614.","journal-title":"J Exp Med"},{"key":"6076_CR11","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1136\/gutjnl-2016-313392","volume":"67","author":"DM Xiang","year":"2018","unstructured":"Xiang DM, Sun W, Ning BF, Zhou TF, Li XF, Zhong W, et al. The HLF\/IL-6\/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis. Gut. 2018;67:1704\u201315.","journal-title":"Gut."},{"key":"6076_CR12","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1136\/gutjnl-2018-317440","volume":"68","author":"DM Xiang","year":"2019","unstructured":"Xiang DM, Sun W, Zhou T, Zhang C, Cheng Z, Li SC, et al. Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance. Gut. 2019;68:1858\u201371.","journal-title":"Gut."},{"key":"6076_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13045-021-01223-x","volume":"15","author":"H Li","year":"2022","unstructured":"Li H, Yang P, Wang J, Zhang J, Ma Q, Jiang Y, et al. HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk. J Hematol Oncol. 2022;15:2.","journal-title":"J Hematol Oncol"},{"key":"6076_CR14","doi-asserted-by":"publisher","first-page":"216144","DOI":"10.1016\/j.canlet.2023.216144","volume":"560","author":"D Xiang","year":"2023","unstructured":"Xiang D, Gu M, Liu J, Dong W, Yang Z, Wang K, et al. m6A RNA methylation-mediated upregulation of HLF promotes intrahepatic cholangiocarcinoma progression by regulating the FZD4\/beta-catenin signaling pathway. Cancer Lett. 2023;560:216144.","journal-title":"Cancer Lett"},{"key":"6076_CR15","doi-asserted-by":"publisher","first-page":"e23980","DOI":"10.1097\/MD.0000000000023980","volume":"100","author":"Q Liu","year":"2021","unstructured":"Liu Q, Ge H, Liu P, Li Y. High Hepatic leukemia factor expression indicates a favorable survival in glioma patients. Medicine (Baltimore). 2021;100:e23980.","journal-title":"Medicine (Baltimore)"},{"key":"6076_CR16","first-page":"e929333","volume":"27","author":"Z Wang","year":"2021","unstructured":"Wang Z, Li X, Chen H, Han L, Ji X, Wang Q, et al. Decreased HLF expression predicts poor survival in lung adenocarcinoma. Med Sci Monit. 2021;27:e929333.","journal-title":"Med Sci Monit"},{"key":"6076_CR17","doi-asserted-by":"publisher","first-page":"eaay3324","DOI":"10.1126\/sciadv.aay3324","volume":"6","author":"H Omori","year":"2020","unstructured":"Omori H, Nishio M, Masuda M, Miyachi Y, Ueda F, Nakano T, et al. YAP1 is a potent driver of the onset and progression of oral squamous cell carcinoma. Sci Adv. 2020;6:eaay3324.","journal-title":"Sci Adv"},{"key":"6076_CR18","doi-asserted-by":"publisher","first-page":"eaaz4589.","DOI":"10.1126\/scitranslmed.aaz4589","volume":"12","author":"MB Nilsson","year":"2020","unstructured":"Nilsson MB, Sun H, Robichaux J, Pfeifer M, McDermott U, Travers J, et al. A YAP\/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Sci Transl Med. 2020;12:eaaz4589.","journal-title":"Sci Transl Med"},{"key":"6076_CR19","doi-asserted-by":"publisher","first-page":"111130","DOI":"10.18632\/oncotarget.22666","volume":"8","author":"YG Eun","year":"2017","unstructured":"Eun YG, Lee D, Lee YC, Sohn BH, Kim EH, Yim SY, et al. Clinical significance of YAP1 activation in head and neck squamous cell carcinoma. Oncotarget. 2017;8:111130\u201343.","journal-title":"Oncotarget."},{"key":"6076_CR20","doi-asserted-by":"publisher","first-page":"6040","DOI":"10.1038\/onc.2015.52","volume":"34","author":"C He","year":"2015","unstructured":"He C, Lv X, Hua G, Lele SM, Remmenga S, Dong J, et al. YAP forms autocrine loops with the ERBB pathway to regulate ovarian cancer initiation and progression. Oncogene. 2015;34:6040\u201354.","journal-title":"Oncogene."},{"key":"6076_CR21","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41388-022-02267-0","volume":"41","author":"Z Liu","year":"2022","unstructured":"Liu Z, Li J, Ding Y, Ma M, Chen J, Lei W, et al. USP49 mediates tumor progression and poor prognosis through a YAP1-dependent feedback loop in gastric cancer. Oncogene. 2022;41:2555\u201370.","journal-title":"Oncogene."},{"key":"6076_CR22","doi-asserted-by":"publisher","first-page":"215640","DOI":"10.1016\/j.canlet.2022.215640","volume":"537","author":"X Xu","year":"2022","unstructured":"Xu X, Wang B, Liu Y, Jing T, Xu G, Zhang L, et al. ETV4 potentiates nuclear YAP retention and activities to enhance the progression of hepatocellular carcinoma. Cancer Lett. 2022;537:215640.","journal-title":"Cancer Lett"},{"key":"6076_CR23","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41388-021-02131-7","volume":"41","author":"YC Lee","year":"2022","unstructured":"Lee YC, Lin SC, Yu G, Zhu M, Song JH, Rivera K, et al. Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP\/TAZ inhibition. Oncogene. 2022;41:757\u201369.","journal-title":"Oncogene."},{"key":"6076_CR24","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1097\/PAI.0000000000000984","volume":"30","author":"Q Wang","year":"2022","unstructured":"Wang Q, Sang W, Xue J, Zhai Y, Hu Y, Su L, et al. The expression and prognostic value of ILK and YAP1 in glioma. Appl Immunohistochem Mol Morphol. 2022;30:e21\u20139.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"6076_CR25","doi-asserted-by":"publisher","first-page":"8517","DOI":"10.1158\/0008-5472.CAN-10-1242","volume":"70","author":"CA Hall","year":"2010","unstructured":"Hall CA, Wang R, Miao J, Oliva E, Shen X, Wheeler T, et al. Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res. 2010;70:8517\u201325.","journal-title":"Cancer Res"},{"key":"6076_CR26","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1038\/onc.2011.8","volume":"30","author":"X Zhang","year":"2011","unstructured":"Zhang X, George J, Deb S, Degoutin JL, Takano EA, Fox SB, et al. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene. 2011;30:2810\u201322.","journal-title":"Oncogene."},{"key":"6076_CR27","doi-asserted-by":"publisher","first-page":"e151591","DOI":"10.1172\/JCI151591","volume":"132","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Wang Y, Zhao G, Tanner EJ, Adli M, Matei D. FOXK2 promotes ovarian cancer stemness by regulating the unfolded protein response pathway. J Clin Invest. 2022;132:e151591.","journal-title":"J Clin Invest"},{"key":"6076_CR28","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.7150\/thno.48101","volume":"11","author":"Y Wen","year":"2021","unstructured":"Wen Y, Hou Y, Yi X, Sun S, Guo J, He X, et al. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells. Theranostics. 2021;11:1795\u2013813.","journal-title":"Theranostics."},{"key":"6076_CR29","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.stem.2017.10.001","volume":"21","author":"JA Brown","year":"2017","unstructured":"Brown JA, Yonekubo Y, Hanson N, Sastre-Perona A, Basin A, Rytlewski JA, et al. TGF-beta-Induced quiescence mediates chemoresistance of tumor-propagating cells in squamous cell carcinoma. Cell Stem Cell. 2017;21:650\u201364.e8.","journal-title":"Cell Stem Cell"},{"key":"6076_CR30","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.jhep.2015.03.036","volume":"63","author":"T Han","year":"2015","unstructured":"Han T, Xiang DM, Sun W, Liu N, Sun HL, Wen W, et al. PTPN11\/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients. J Hepatol. 2015;63:651\u201360.","journal-title":"J Hepatol"},{"key":"6076_CR31","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jhep.2021.11.010","volume":"76","author":"Y Liu","year":"2022","unstructured":"Liu Y, Zhuo S, Zhou Y, Ma L, Sun Z, Wu X, et al. Yap-Sox9 signaling determines hepatocyte plasticity and lineage-specific hepatocarcinogenesis. J Hepatol. 2022;76:652\u201364.","journal-title":"J Hepatol"},{"key":"6076_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12692","volume":"7","author":"L Qu","year":"2016","unstructured":"Qu L, Wu Z, Li Y, Xu Z, Liu B, Liu F, et al. A feed-forward loop between lncARSR and YAP activity promotes expansion of renal tumour-initiating cells. Nat Commun. 2016;7:12692.","journal-title":"Nat Commun"},{"key":"6076_CR33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.canlet.2020.08.026","volume":"492","author":"P Tocci","year":"2020","unstructured":"Tocci P, Cianfrocca R, Sestito R, Rosano L, Di Castro V, Blandino G, et al. Endothelin-1 axis fosters YAP-induced chemotherapy escape in ovarian cancer. Cancer Lett. 2020;492:84\u201395.","journal-title":"Cancer Lett"},{"key":"6076_CR34","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.stem.2020.07.003","volume":"27","author":"P Cheung","year":"2020","unstructured":"Cheung P, Xiol J, Dill MT, Yuan WC, Panero R, Roper J, et al. Regenerative reprogramming of the intestinal stem cell state via hippo signaling suppresses metastatic colorectal cancer. Cell Stem Cell. 2020;27:590\u2013604.e9.","journal-title":"Cell Stem Cell"},{"key":"6076_CR35","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2015.07.013","volume":"162","author":"HW Park","year":"2015","unstructured":"Park HW, Kim YC, Yu B, Moroishi T, Mo JS, Plouffe SW, et al. Alternative Wnt signaling activates YAP\/TAZ. Cell. 2015;162:780\u201394.","journal-title":"Cell."},{"key":"6076_CR36","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.omtn.2020.11.024","volume":"23","author":"L Wang","year":"2021","unstructured":"Wang L, Liu Y, Li H, Zhang C, Wang H, Dai S, et al. miR-4478 sensitizes ovarian cancer cells to irradiation by inhibiting Fus and attenuating autophagy. Mol Ther Nucleic Acids. 2021;23:1110\u20139.","journal-title":"Mol Ther Nucleic Acids"},{"key":"6076_CR37","doi-asserted-by":"publisher","first-page":"881496","DOI":"10.3389\/fonc.2022.881496","volume":"12","author":"YY Liu","year":"2022","unstructured":"Liu YY, Zhao RF, Liu C, Zhou J, Yang L, Li L. MiR-320b and miR-320d as biomarkers to predict and participate in the formation of platinum resistance in ovarian cancer patients. Front Oncol. 2022;12:881496.","journal-title":"Front Oncol"},{"key":"6076_CR38","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1038\/onc.2011.523","volume":"31","author":"S Zhang","year":"2012","unstructured":"Zhang S, Shan C, Kong G, Du Y, Ye L, Zhang X. MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-kappaB-inducing kinase (NIK). Oncogene. 2012;31:3607\u201320.","journal-title":"Oncogene."},{"key":"6076_CR39","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.3892\/ol.2016.5085","volume":"12","author":"M Yi","year":"2016","unstructured":"Yi M, Li M, Long X, Ye J, Cui J, Wei W, et al. miR-520e regulates cell proliferation, apoptosis and migration in breast cancer. Oncol Lett. 2016;12:3543\u20138.","journal-title":"Oncol Lett"},{"key":"6076_CR40","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1200\/JCO.21.00605","volume":"39","author":"O Zivanovic","year":"2021","unstructured":"Zivanovic O, Chi DS, Zhou Q, Iasonos A, Konner JA, Makker V, et al. Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK team ovary phase II study. J Clin Oncol. 2021;39:2594\u2013604.","journal-title":"J Clin Oncol"},{"key":"6076_CR41","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1001\/jamaoncol.2021.0696","volume":"7","author":"C Falandry","year":"2021","unstructured":"Falandry C, Rousseau F, Mouret-Reynier MA, Tinquaut F, Lorusso D, Herrstedt J, et al. Efficacy and safety of first-line single-agent carboplatin vs carboplatin plus paclitaxel for vulnerable older adult women with ovarian cancer: a GINECO\/GCIG randomized clinical trial. JAMA Oncol. 2021;7:853\u201361.","journal-title":"JAMA Oncol"},{"key":"6076_CR42","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1053\/j.gastro.2023.01.041","volume":"164","author":"J Wang","year":"2023","unstructured":"Wang J, Yu H, Dong W, Zhang C, Hu M, Ma W, et al. N6-methyladenosine-mediated up-regulation of FZD10 regulates liver cancer stem cells' properties and lenvatinib resistance through WNT\/beta-catenin and hippo signaling pathways. Gastroenterology. 2023;164:990\u20131005.","journal-title":"Gastroenterology"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06076-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06076-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06076-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T15:19:50Z","timestamp":1694704790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06076-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["6076"],"URL":"https:\/\/doi.org\/10.1038\/s41419-023-06076-5","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,14]]},"assertion":[{"value":"19 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Study protocols were approved by the Ethics Committee of the First Affiliated Hospital of China Medical University. Informed consent was obtained from all the participants included in this study according to the committee regulations. All animal experiments and relevant details were conducted in accordance with the approved guidelines and were approved by the Committee on Animal Care and Use of China Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All contributors have agreed to publish this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"606"}}